Molecular Testing
We have developed two unprecedented molecular tests to predict drug response in standard cancer chemotherapy with platinum drugs. This method will improve personalized treatment by identifying patients who are responsive to standard chemotherapy regimen. Thus, our technology allows physicians to confidently avoid prescribing ineffective drugs based on the patient’s molecular characteristics. This method is based on our discovery of two proprietary "Glycan Biomarkers," whose cell-surface overexpression is associated with drug susceptibility.
Our studies have focused on ovarian cancer, however evidence suggests that our method may be applicable to a wide range of cancers, such as lung, testicular, bladder, head and neck, melanoma, late-stage cervical, lymphomas and myelomas, which are treated by standard chemotherapy similar to ovarian cancer.
